81_FR_60881 81 FR 60710 - Government-Owned Inventions; Availability for Licensing

81 FR 60710 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 171 (September 2, 2016)

Page Range60710-60711
FR Document2016-21114

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 81 Issue 171 (Friday, September 2, 2016) 
[Federal Register Volume 81, Number 171 (Friday, September 2, 2016)]
[Notices]
[Pages 60710-60711]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-21114]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the National Heart, Lung and Blood 
Institute, Office of Technology Transfer and Development, National 
Institutes of Health, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 
20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Microscopy Systems for Instant Internal Reflection Fluorescence/
Structured Illumination

    Description of Technology: Structured illumination microscopy (SIM) 
is a method that uses sharply patterned light and post-processing of 
images to enhance image resolution (in its linear form, doubling 
resolution). In traditional SIM, a series of images are acquired with a 
camera and computationally processed to improve resolution. This 
implementation of SIM has also been combined with total internal 
reflection fluorescence (TIRF), but the implementation still requires 
raw images relative to normal TIRF microscopy, thereby slowing 
acquisition 9-fold relative to conventional, diffraction-limited 
imaging. This TIRF/

[[Page 60711]]

SIM system includes a radial aperture block positioned at a plane 
conjugate to the back focal plane of the objective lens, thus allowing 
only high-angle marginal annular light beams from a laser source to 
excite the sample. The radial aperture block can be replaced with a 
digital micromirror device for varying the evanescent wave to allow 
nanometric localization of features in the axial direction. A spatial 
light modulator (SLM) can be used to alter the phase of the excitation 
to optimally induce evanescent, patterned excitation at the sample. 
Various embodiments of the TIRF/SIM system allows for high-speed, 
super-resolution microscopy at very high signal-to-noise (SNR) ratios 
for biological applications within ~200 nm (e.g., the evanescent wave 
decay length) distance of a coverslip surface.
    Potential Commercial Applications:  High speed microscopy.
    Competitive Advantages:  Low cost of manufacture.
    Development Stage:  Prototype.
    Inventors: Hari Shroff (NIBIB), Justin Taraska (NHBLI), John 
Giannini (NIBIB), Yicong Wu (NIBIB), Abhishek Kumar (NIBIB), Min Guo 
(NIBIB).

Publications

1. Christensen RP, et al. Untwisting the Caenorhabditis elegans embryo. 
Elife. 2015 Dec 3;4. [PMID: 26633880]
2. Curd A., et al. Construction of an instant structured illumination 
microscope. Methods. 2015 Oct 15;88:37-47. [PMID: 26210400]

    Intellectual Property: HHS Reference No. E-006-2016/0.
     US Provisional Patent Application No. 62/378,307 filed 23 
Aug 2016.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: August 29, 2016.
Michael Shmilovich,
National Heart, Lung and Blood Institute, Office of Technology Transfer 
and Development, National Institutes of Health.
[FR Doc. 2016-21114 Filed 9-1-16; 8:45 am]
 BILLING CODE 4140-01-P

60710 Federal Register / Vol. 81, No. 171 / Friday, September 2, 2016 / Notices Jason E. Bennett, license may be worldwide, and the field Dated: August 29, 2016. Director, Division of the Executive Secretariat. of use may be limited to ‘‘Conjugate of Richard U. Rodriguez, [FR Doc. 2016–21168 Filed 9–1–16; 8:45 am] Alpha-V beta-3 antagonist NIH–CC–013 Associate Director, Technology Transfer BILLING CODE 4165–15–P for theranostic application to diagnose, Center, National Cancer Institute. prevent and treat oncological, [FR Doc. 2016–21113 Filed 9–1–16; 8:45 am] infectious, ocular and cardiovascular BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND disorders.’’ HUMAN SERVICES DATES: Only written comments and/or DEPARTMENT OF HEALTH AND National Institutes of Health applications for a license which are HUMAN SERVICES received by the NCI Technology Prospective Grant of Exclusive Patent National Institutes of Health Transfer Center on or before September License: Development of Integrin αvβ3 19, 2016 will be considered. Antagonists for Use in Imaging and Government-Owned Inventions; Therapy ADDRESSES: Requests for copies of the Availability for Licensing AGENCY: National Institutes of Health, patent application(s), inquiries, AGENCY: National Institutes of Health, HHS. comments, and other materials relating HHS. to the contemplated exclusive license ACTION: Notice. ACTION: Notice. should be directed to: Jaime M. Greene, SUMMARY: This is notice, in accordance M.S., Senior Licensing and Patenting SUMMARY: The inventions listed below with 35 U.S.C. 209(c)(1) and 37 CFR Manager, Technology Transfer Center, are owned by an agency of the U.S. part 404.7(a)(1)(i), that the National National Cancer Institute, 9609 Medical Government and are available for Cancer Institute (NCI) and the Clinical Center Drive, Rockville, MD 20850; licensing in the U.S. in accordance with Center (CC), National Institutes of telephone: 240–276–6633; email: 35 U.S.C. 209 and 37 CFR part 404 to Health, Department of Health and greenejaime@mail.nih.gov. achieve expeditious commercialization Human Services, are contemplating the of results of federally-funded research grant of an exclusive license to SUPPLEMENTARY INFORMATION: This and development. Foreign patent Advanced Imaging Projects, LLC, a technology concerns small molecule applications are filed on selected company having a place of business in compositions that are antagonists for the inventions to extend market coverage Boca Raton, FL, to practice the receptor integrin avb3. Integrins are for companies and may also be available inventions embodied in the following functional molecules for cell adhesion for licensing. patent applications: activity that are expressed by the FOR FURTHER INFORMATION CONTACT: majority of normal and cancer cells. Licensing information and copies of the Intellectual Property They are trans-membrane heterodimer U.S. patent applications listed below U.S. Patent No. 7,300,940, filed 4 receptors that include two subunits, a may be obtained by writing to the August 2004, titled ‘‘Integrin a-v b-3 and b chains, that primarily allow cell indicated licensing contact at the antagonists for use in imaging and adhesion to extracellular matrix National Heart, Lung and Blood therapy’’ (HHS Ref. No.: E–170–2004/0– components such as fibrillar collagen, Institute, Office of Technology Transfer US–01); vitronectin and osteopontin. This PCT Application No. PCT/US2005/ and Development, National Institutes of technology may be useful for the Health, 31 Center Drive Room 4A29, 027868, filed 3 August 2005, now development of diagnostics and MSC2479, Bethesda, MD 20892–2479; abandoned, titled ‘‘Integrin a-v b-3 antagonists for use in imaging and therapeutics for cancers and other telephone: 301–402–5579. A signed therapy’’ (HHS Ref. No.: E–170–2004/0– conditions involving the integrin avb3. Confidential Disclosure Agreement may PCT–02); The prospective exclusive license will be required to receive copies of the Switzerland Patent No. 1781622, be royalty bearing and will comply with patent applications. titled ‘‘Integrin a-v b-3 antagonists for the terms and conditions of 35 U.S.C. SUPPLEMENTARY INFORMATION: use in imaging and therapy’’ filed 4 209 and 37 CFR part 404.7. The Technology descriptions follow. March 2007, issued 18 May 2011 (HHS prospective exclusive license may be Microscopy Systems for Instant Ref. No.: E–170–2004/0–CH–04); granted unless within fifteen (15) days Internal Reflection Fluorescence/ Germany Patent No. 602005028137.1, from the date of this published notice, Structured Illumination titled ‘‘Integrin a-v b-3 antagonists for the NIH receives written evidence and use in imaging and therapy’’ filed 4 Description of Technology: Structured argument that establishes that the grant illumination microscopy (SIM) is a March 2007, issued 18 May 2011 (HHS of the license would not be consistent method that uses sharply patterned light Ref. No.: E–170–2004/0–DE–05); France Patent No. 1781622, titled with the requirements of 35 U.S.C. 209 and post-processing of images to ‘‘Integrin a-v b-3 antagonists for use in and 37 CFR part 404.7. enhance image resolution (in its linear imaging and therapy’’ filed 4 March Complete applications for a license in form, doubling resolution). In 2007, issued 18 May 2011 (HHS Ref. the prospective field of use that are filed traditional SIM, a series of images are No.: E–170–2004/0–FR–060); and in response to this notice will be treated acquired with a camera and Ireland Patent No. 1781622, titled as objections to the grant of the computationally processed to improve ‘‘Integrin a-v b-3 antagonists for use in resolution. This implementation of SIM mstockstill on DSK3G9T082PROD with NOTICES contemplated Exclusive Patent License imaging and therapy’’ filed 4 March Agreement. Comments and objections has also been combined with total 2007, issued 18 May 2011 (HHS Ref. submitted to this notice will not be internal reflection fluorescence (TIRF), No.: E–170–2004/0–IE–07). made available for public inspection but the implementation still requires The patent rights in these inventions and, to the extent permitted by law, will raw images relative to normal TIRF have been assigned to the Government microscopy, thereby slowing acquisition not be released under the Freedom of of the United States of America. The 9-fold relative to conventional, Information Act, 5 U.S.C. 552. territory of the prospective exclusive diffraction-limited imaging. This TIRF/ VerDate Sep<11>2014 18:25 Sep 01, 2016 Jkt 238001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\02SEN1.SGM 02SEN1

Federal Register / Vol. 81, No. 171 / Friday, September 2, 2016 / Notices 60711 SIM system includes a radial aperture The meeting will be closed to the Name of Committee: National Institute of block positioned at a plane conjugate to public in accordance with the Allergy and Infectious Diseases Special the back focal plane of the objective provisions set forth in sections Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement lens, thus allowing only high-angle 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., (U01). marginal annular light beams from a as amended. The grant applications and Date: September 26, 2016. laser source to excite the sample. The the discussions could disclose Time: 10:00 a.m. to 3:00 p.m. radial aperture block can be replaced confidential trade secrets or commercial Agenda: To review and evaluate grant with a digital micromirror device for property such as patentable material, applications. varying the evanescent wave to allow and personal information concerning Place: National Institutes of Health, 5601 nanometric localization of features in individuals associated with the grant Fishers Lane, Rockville, MD 20892 the axial direction. A spatial light applications, the disclosure of which (Telephone Conference Call). Contact Person: Lynn Rust, Ph.D., modulator (SLM) can be used to alter would constitute a clearly unwarranted Scientific Review Officer, Scientific Review the phase of the excitation to optimally invasion of personal privacy. Program, Division of Extramural Activities, induce evanescent, patterned excitation Name of Committee: National Institute of Room 3G42A, National Institutes of Health/ at the sample. Various embodiments of Allergy and Infectious Diseases Special NIAID, 5601 Fishers Lane, MSC 9823, the TIRF/SIM system allows for high- Emphasis Panel, NIAID Clinical Trial Bethesda, MD 20892–9823, (240) 669–5069, speed, super-resolution microscopy at Implementation Cooperative Agreement lrust@niaid.nih.gov. very high signal-to-noise (SNR) ratios (U01). (Catalogue of Federal Domestic Assistance for biological applications within ∼200 Date: October 5, 2016. Program Nos. 93.855, Allergy, Immunology, Time: 9:00 a.m. to 11:00 a.m. and Transplantation Research; 93.856, nm (e.g., the evanescent wave decay Agenda: To review and evaluate grant length) distance of a coverslip surface. Microbiology and Infectious Diseases applications. Research, National Institutes of Health, HHS) Potential Commercial Applications: Place: National Institutes of Health, 5601 • High speed microscopy. Fishers Lane, Rockville, MD 20892, Dated: August 29, 2016. Competitive Advantages: • Low cost (Telephone Conference Call). Natasha M. Copeland, of manufacture. Contact Person: Lynn Rust, Ph.D., Program Analyst, Office of Federal Advisory Development Stage: • Prototype. Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Committee Policy. Inventors: Hari Shroff (NIBIB), Justin Taraska (NHBLI), John Giannini (NIBIB), Room 3G42A, National Institutes of Health/ [FR Doc. 2016–21119 Filed 9–1–16; 8:45 am] NIAID, 5601 Fishers Lane, MSC 9823, BILLING CODE 4140–01–P Yicong Wu (NIBIB), Abhishek Kumar Bethesda, MD 20892–9823, (240) 669–5069, (NIBIB), Min Guo (NIBIB). lrust@niaid.nih.gov. Publications (Catalogue of Federal Domestic Assistance DEPARTMENT OF HEALTH AND Program Nos. 93.855, Allergy, Immunology, HUMAN SERVICES 1. Christensen RP, et al. Untwisting the and Transplantation Research; 93.856, Caenorhabditis elegans embryo. Microbiology and Infectious Diseases National Institutes of Health Elife. 2015 Dec 3;4. [PMID: Research, National Institutes of Health, HHS) 26633880] Dated: August 29, 2016. National Institute of Allergy and 2. Curd A., et al. Construction of an Infectious Diseases; Notice of Closed Natasha M. Copeland, instant structured illumination Meeting microscope. Methods. 2015 Oct Program Analyst, Office of Federal Advisory Committee Policy. Pursuant to section 10(d) of the 15;88:37–47. [PMID: 26210400] [FR Doc. 2016–21117 Filed 9–1–16; 8:45 am] Federal Advisory Committee Act, as Intellectual Property: HHS Reference No. E–006–2016/0. BILLING CODE 4140–01–P amended (5 U.S.C. App.), notice is • US Provisional Patent Application hereby given of the following meeting. No. 62/378,307 filed 23 Aug 2016. The meeting will be closed to the DEPARTMENT OF HEALTH AND public in accordance with the Licensing Contact: Michael HUMAN SERVICES provisions set forth in sections Shmilovich, Esq, CLP; 301–435–5019; shmilovm@mail.nih.gov. 552b(c)(4) and 552b(c)(6), title 5 U.S.C., National Institutes of Health as amended. The grant applications and Dated: August 29, 2016. the discussions could disclose Michael Shmilovich, National Institute of Allergy and Infectious Diseases; Notice of Closed confidential trade secrets or commercial National Heart, Lung and Blood Institute, property such as patentable material, Office of Technology Transfer and Meeting and personal information concerning Development, National Institutes of Health. Pursuant to section 10(d) of the individuals associated with the grant [FR Doc. 2016–21114 Filed 9–1–16; 8:45 am] Federal Advisory Committee Act, as applications, the disclosure of which BILLING CODE 4140–01–P amended (5 U.S.C. App.), notice is would constitute a clearly unwarranted hereby given of the following meeting. invasion of personal privacy. The meeting will be closed to the Name of Committee: National Institute of DEPARTMENT OF HEALTH AND public in accordance with the Allergy and Infectious Diseases Special HUMAN SERVICES provisions set forth in sections Emphasis Panel NIAID Clinical Trial 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Implementation Cooperative Agreement National Institutes of Health as amended. The grant applications and (U01). the discussions could disclose Date: September 28, 2016. mstockstill on DSK3G9T082PROD with NOTICES National Institute of Allergy and Time: 10:00 a.m. to 12:00 p.m. Infectious Diseases; Notice of Closed confidential trade secrets or commercial property such as patentable material, Agenda: To review and evaluate grant Meeting applications. and personal information concerning Place: National Institutes of Health, 5601 Pursuant to section 10(d) of the individuals associated with the grant Fishers Lane, Rockville, MD 20892 Federal Advisory Committee Act, as applications, the disclosure of which (Telephone Conference Call). amended (5 U.S.C. App.), notice is would constitute a clearly unwarranted Contact Person: Lynn Rust, Ph.D., hereby given of the following meeting. invasion of personal privacy. Scientific Review Officer, Scientific Review VerDate Sep<11>2014 18:25 Sep 01, 2016 Jkt 238001 PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 E:\FR\FM\02SEN1.SGM 02SEN1


Document Created: 2018-02-09 11:55:33
Document Modified: 2018-02-09 11:55:33
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the National Heart, Lung and Blood Institute, Office of Technology Transfer and Development, National Institutes of Health, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.
FR Citation81 FR 60710 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR